INTEGRATED BIOPHARMA INC financials

INBP CIK 0001016504

Source: EDGAR filings · Built 2026-06-19T01:04:38Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 1.87M 348.00K 1.08M 3.60M 2.68M 931.00K
EBITDA 2.34M 558.00K 471.00K 3.08M 6.12M 3.57M
Working Capital 14.52M 11.75M 11.54M 11.36M 8.76M 3.36M
Net Debt -2.60M 121.00K 1.41M 1.64M 5.80M 10.85M
Gross Margin 10.23% 7.72% 8.01% 11.65% 14.92% 12.75%
Operating Margin 3.72% 0.50% 0.24% 4.88% 9.10% 6.18%
Net Margin 1.49% 0.22% -0.07% 6.82% 12.61% 7.78%
Return on Equity (ROE) 3.98% 0.58% -0.18% 20.66% 55.90% 67.71%
Return on Assets (ROA) 3.24% 0.43% -0.13% 15.20% 31.50% 17.90%
Current Ratio 4.42× 2.92× 3.39× 3.16× 1.95× 1.26×
Debt-to-Equity 0.05× 0.09× 0.14× 0.11× 0.42× 1.85×
Effective Tax Rate 60.81% 58.21% 134.00% -47.79% -10.57% -33.03%
Cash Conversion Ratio 2.56× 8.42× -36.24× 1.07× 0.38× 0.33×
Accruals Ratio -0.05× -0.03× -0.05× -0.01× 0.20× 0.12×
SBC % of Revenue 0.34% 0.50% 0.63% 0.66% 0.36% 0.11%
CapEx Coverage 10.38× 1.58× 8.16× 8.42× 8.24× 3.28×
Free Cash Flow Per Share $0.06 $0.01 $0.04 $0.11 $0.08 $0.03

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cost of Goods and Services Sold 48.79M 46.43M 46.61M 49.69M 54.08M 46.04M
Gross Profit 5.56M 3.88M 4.06M 6.55M 9.48M 6.73M
Selling, General and Administrative Expense 3.54M 3.63M 3.94M 3.81M 3.70M 3.47M
Operating Income (Loss) 2.02M 251.00K 120.00K 2.75M 5.78M 3.26M
Income Tax Expense (Benefit) 1.25M 156.00K 134.00K -1.24M -766.00K -1.02M
Net Income (Loss) Attributable to Parent 808.00K 112.00K -34.00K 3.84M 8.01M 4.11M
Earnings Per Share, Basic $0.03 $0.00 $0.00 $0.13 $0.27 $0.14
Weighted Average Number of Shares Outstanding, Basic 30.30M 30.07M 29.95M 29.84M 29.70M 29.57M
Earnings Per Share, Diluted $0.03 $0.00 $0.00 $0.12 $0.25 $0.13
Weighted Average Number of Shares Outstanding, Diluted 31.17M 30.87M 29.95M 32.32M 32.11M 31.16M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 3.62M 1.68M 1.32M 331.00K 210.00K 402.00K
Assets, Current 18.76M 17.88M 16.37M 16.63M 18.00M 16.46M
Assets 24.90M 26.21M 26.21M 25.25M 25.44M 22.94M
Long-term Debt 0 101.00K 3.64M 8.34M
Liabilities, Current 4.25M 6.12M 4.83M 5.26M 9.24M 13.10M
Long-term Debt, Excluding Current Maturities 7.00K 53.00K 0 1.44M
Liabilities 4.58M 6.97M 6.57M 6.67M 11.11M 16.88M
Stockholders' Equity Attributable to Parent 20.32M 19.24M 18.86M 18.57M 14.33M 6.07M
Common Stock, Shares, Outstanding 31.06M 30.10M 29.95M 29.95M 29.80M 29.65M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 2.06M 943.00K 1.23M 4.09M 3.05M 1.34M
Payments to Acquire Property, Plant, and Equipment 191.00K 553.00K 116.00K 486.00K 295.00K 214.00K
Net Cash Provided by (Used in) Investing Activities -205.00K -553.00K -111.00K -465.00K -199.00K -110.00K
Net Cash Provided by (Used in) Financing Activities 78.00K -29.00K -136.00K -3.50M -3.04M -1.30M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (INBP CIK 0001016504), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

ALBT

AVALON GLOBOCARE CORP.

GEV

GE Vernova Inc.

PMT

PennyMac Mortgage Investment Trust